Immunotherapy in the Age of COVID-19

Patients with EGFR-mutated non–small cell lung cancer had a median event-free survival of 30.8 months in the durvalumab arm and 19.6 months in the placebo arm.

Heather Santone breaks down some of the barriers that geriatric patients with cancer face—and how nurse navigators can help them overcome these obstacles.

The pathological complete response among patients who received durvalumab plus chemotherapy was 17.2% vs 4.3% in the placebo plus chemotherapy arm.

Shawna Douglas, BSN, RN, discusses the role that nurse navigators play in caring for patients with head and neck cancer.

The confirmed objective response rate with repotrectinib was 79% among tyrosine kinase inhibitor (TKI)-naïve patients and 38% among TKI-pretreated patients.

The median progression-free survival was 25.5 months with osimertinib plus chemotherapy and 16.7 months with osimertinib alone.